Memorial Sloan Kettering Cancer Center (MSK) is a free-standing NCI-designated Comprehensive Cancer Center dedicated to improving the standards of cancer treatment, prevention and control. MSK?s research programs are grouped into three categories: Basic Research (Regulation of Cell Behavior, Developmental and Stem Cell Biology, Genomic Integrity, and Structural and Chemical Biology); Bridge Research (Cancer Biology and Experimental Pathology, Experimental Therapeutics, Immunology and Transplantation, and Imaging and Radiation Sciences); and Patient-Oriented Research (Clinical Research and Population Science Research). The programs are designed to optimize the use of a large patient population and an extensive, multi-disciplinary staff of clinical and laboratory-based investigators. MSK seeks to encourage the application of scientific discoveries in a way that advances the prevention, detection, diagnosis, and treatment of the many forms of cancer that are relevant to the population in our catchment area. Scientific work in the 10 research programs depends on services provided by 26 core facilities. We are requesting funding from the Cancer Center Support Grant (CCSG) for 20 of these core facilities. Over the next five years, MSK will continue to enhance its clinical and research facilities and its research and training programs in emerging research areas. Support is requested to provide developmental funding for the support of newly recruited investigators in computational biology, to support cross-disciplinary pilot projects in population science research, and to support the core facilities.
Memorial Sloan Kettering Cancer Center (MSK) is a free-standing institution dedicated to the control of cancer through inpatient and outpatient care, clinical and research training programs, and a broad spectrum of research activities. Through these activities, MSK seeks to reduce the burden of cancer throughout our catchment area and the nation.
|Pak, Linda M; Gonen, Mithat; Seier, Kenneth et al. (2018) Can physician gestalt predict survival in patients with resectable pancreatic adenocarcinoma? Abdom Radiol (NY) 43:2113-2118|
|Thomas, Rozario; Marks, Daniel Henry; Chin, Yvette et al. (2018) Whole chromosome loss and associated breakage-fusion-bridge cycles transform mouse tetraploid cells. EMBO J 37:201-218|
|Shoag, Jonathan; Liu, Deli; Blattner, Mirjam et al. (2018) SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG. J Clin Invest 128:381-386|
|Abreu, Carla M; Prakash, Rohit; Romanienko, Peter J et al. (2018) Shu complex SWS1-SWSAP1 promotes early steps in mouse meiotic recombination. Nat Commun 9:3961|
|Katsoulakis, Evangelia; Leeman, Jonathan E; Lok, Benjamin H et al. (2018) Long-term outcomes in oral cavity squamous cell carcinoma with adjuvant and salvage radiotherapy after surgery. Laryngoscope 128:2539-2545|
|Huicochea Castellanos, Sandra; Corrias, Giuseppe; Ulaner, Gary A et al. (2018) Detection of recurrent pancreatic cancer: value of second-opinion interpretations of cross-sectional images by subspecialized radiologists. Abdom Radiol (NY) :|
|Hoseini, Sayed Shahabuddin; Guo, Hongfen; Wu, Zhihao et al. (2018) A potent tetravalent T-cell-engaging bispecific antibody against CD33 in acute myeloid leukemia. Blood Adv 2:1250-1258|
|Attiyeh, Marc A; Fernández-Del Castillo, Carlos; Al Efishat, Mohammad et al. (2018) Development and Validation of a Multi-institutional Preoperative Nomogram for Predicting Grade of Dysplasia in Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas: A Report from The Pancreatic Surgery Consortium. Ann Surg 267:157-163|
|Tollinche, Luis; Tan, KaySee; Han, Austin et al. (2018) Analyzing Volatile Anesthetic Consumption by Auditing Fresh Gas Flow: An Observational Study at an Academic Hospital. Int J Anesth Anesth 5:|
|Tadros, Audree B; Wen, Hannah Y; Morrow, Monica (2018) Breast Cancers of Special Histologic Subtypes Are Biologically Diverse. Ann Surg Oncol 25:3158-3164|
Showing the most recent 10 out of 8799 publications